TSHA-102 Gets FDA Fast Track Designation in Rett Syndrome
TSHA-102 has previously received orphan drug and rare pediatric disease designations from the agency and is being investigated in the REVEAL phase 1/2 trial (NCT05606614).
CAR-T for NMOSD Demonstrates Manageable Safety in Phase 1 Trial
It was previously announced that CT103A received FDA clearance of its investigational new drug application for the treatment of relapsed/refractory (r/r) multiple myeloma.